HLB Therapeutics will be traded using the single-price trading method for three trading days starting from the 12th, as it has been designated as a short-term overheated stock.

According to a disclosure by the Korea Exchange, HLB Therapeutics was designated as a short-term overheated stock after meeting the designation criteria set forth in Article 28-2 of the Enforcement Rules of the KOSDAQ Market Business Regulations.

Accordingly, the single-price trading method, in which transactions are executed in 30-minute intervals, will apply for three trading days from the 12th to the 14th.

The short-term overheated stock designation ends, in principle, on the 14th and is lifted from the next trading day. However, if the closing price on the 14th, the final day of the designation, is 20% or higher than the closing price on the day prior to the designation date, the designation period is extended by three trading days. The extension is limited to one time, and the single-price trading method continues to apply during the extension period.

In addition, even if trading is suspended during the single-price trading period, the number of suspension days is included in the single-price trading period. Upon the end of the designation period, no separate market announcement will be made.